🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Limoges
NCT07675018 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\<2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years old; Hospitalized or admitted to the Emergency department; * Diagnosis of non-severe (qSOFA \< 2) urinary tract infection coupled with fever ≥ 38°C or \< 36°C * Presence of bacteria in the fresh urine sample and/or GNB on the Gram stain * Empirical parenteral antibiotic therapy required; Hospitalization required; * Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months * Informed consent of the patient or their representative Exclusion Criteria: * Pregnant and/or breastfeeding * Neutropenia (absolute neutrophil count \< 500 / mm3) * Severe UTI with sepsis (qSOFA ≥ 2) or septic shock * Urinary derivation required (ureteral catheter/per-cutaneous nephrostomy) except for simple urinary catheterization * Known allergy to β-lactams * Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months * Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem * Not affiliated to Social Security
💊

What it tests

  • Detection of integrons
  • Gold standard
📍

Where

7 sites
CHRU Tours, Hôpital Trousseau
Chambray-lès-Tours, France
Grenoble university hospital
La Tronche, France
Limoges university hospital
Limoges, France
Hopital lariboisière
Paris, France
Hôpital Saint Louis - APHP
Paris, France
Groupe Hospitalier Universitaire Bichat-Claude Bernard - APHP
Paris, France
CHU de Reims
Reims, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy